2485 results about "Lactobacillus" patented technology

The present invention relates in one aspect to a fast acidifying lactic acid bacterium that generates a viscosity in fermented milk greater than about 62 Pa·s after 14 days of storage at 6° C.

The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.

The invention discloses a compound microbial culture starter and application thereof, which belong to an application of a beneficial microbial preparation at low cost. The active microorganism of the compound microbial culture starter comprises saccharmyces cerevisiae, bacillus subtilis, bacillus natto and lactococcus lactis. The compound microbial culture starter can be used for livestock and poultry raising beds, feeds addictive and other aspects and is characterized by reducing the cost input of users on the culture starter and having stable effect.

The invention relates to a kitchen waste recycling automatic treating all-in-one machine and a treatment process thereof. The all-in-one machine comprises a crushing device, a squeezing device, an oil-water separating device and a biological treating device, wherein the crushing device is used for crushing kitchen waste into residue bodies with the food particle size of 0.1 to 0.3 millimeters; liquid in solid residues squeezed by the squeezing device accounts for 7 to 15 percent of the total weight of solid residues; the solid residues enter the biological treating device for treatment finally, and a microbial agent is put into a fermentation tank in the biological treating device, heated and subjected to batch-type stirring; the microbial agent consists of actinomycetes, lactobacillus, saccharomycetes and photosynthetic bacteria and are fed in a mass ratio of 3:5:7:4; 0.01 to 2 mass parts of the microbial agent are added into 100 mass parts of solid residues; and the fermentation time of the microbial agent is 3 to 15 hours. The integrated equipment is small in size, compost time can be shortened greatly, and the treatment efficiency is improved.

The invention discloses a matrimony vine composite health care enzyme and a preparation method thereof. The matrimony vine composite health care enzyme comprises the raw materials of 1-16 parts of matrimony vine, 0-12 parts of red date, 0-1 part of licorice, 0-4 parts of black rice, 0-2 parts of white hyacinth bean, 0-5 parts of oat, 0-5 parts of tartary buckwheat, 0-3 parts of cassia seed, 0-1 part of chrysanthemum, a lot of honey, a lot of granulated sugar, a lot of high fructose corn syrup and a lot of oligosaccharide. The method comprises the following steps: beating matrimony vine and red date, extracting chrysanthemum and licorice, immersing the cereal and steaming, inoculating Aspergillus oryzae and Kluyveromyces Marxianus yeast and fermenting, and performing pulp refining, sterilizing a mixed liquor, and inoculating lactics for enclosed insulation and fermentation to obtain the matrimony vine composite health care enzyme. The matrimony vine composite health care enzyme stock solution can be prepared to a matrimony vine composite health care enzyme concentrated slurry, an enzyme paste and enzyme powder, and the enzyme powder can be prepared to a matrimony vine composite health care enzyme effervescent tablet, a particle electuary, a chewing tablet, a lozenge and a capsule.

The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

The present invention belongs to the field of food biotechnology and is especioally microbial conversion process of preparing gamma-amino butyric acid. Gamma-amino butyric acid is prepared with lactic acid bacteria or lactic acid bacteria and saccharomycete mixture as bacteria strain, sodium L-glutamate as converting substrate and through fermentating process with fermenting medium with carbon source, nitrogen source and inorganic salt. The selected lactic acid bacteria can growth well in MRS or PYG culture medium at 25-40 deg.c and may be used as culture seed liquid. Of the culture medium, the carbon source is glucose, and the nitrogen source may be one or several selected from corn paste, yeast paste, defatted peanut cake powder, etc. After fermentation, the concentration of gamma-aminoacid may reach as high as 300-500 ml / 100 ml.

The invention discloses a fermented feed additive, a preparation method and application thereof. The fermented feed additive is prepared by fermenting mixed strains and mixed auxiliary materials consisting of monosodium glutamate protein, bean pulp, bran, cottonseed meal, corn fibers, rice bran and powdered rice hulls, wherein the mixed strains are obtained by mixing activated strains of lactobacillus acidophilus, lactobacillus planetarium, lactobacillus casei, saccharomyces cerevisiae, bacillus subtilis and bacillus licheniformis in a proportion of (1-5): (1-5): (1-5): (1-5): (1-5): (1-5); and the dosage of the fermented feed additive is 5 to 100 percent of the weight of the animal feed when used for the animal feed. According to the fermented feed additive, the bean pulp, the bran, the cottonseed meal and other raw auxiliary materials are sufficiently utilized, so that the food consumption in the animal feeding process is reduced; the fermented feed additive can be used to partiallyor completely replace the animal feed, and antibiotic medicaments can be reduced or prevented from being used; and no medicament is left, so that the feeding cost of farmers is reduced.

A high flux of metabolites from pyruvate to 2,3-butanediol in Lactobacillus plantarum was achieved through genetic engineering. Substantial elimination of lactate dehydrogenase activity in the presence of heterologously expressed butanediol dehydrogenase activity led to 2,3 butanediol production that was at least 49% of the total of major pyruvate-derived products.

The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

A hygiene tissue to be used for cleaning and caring of the skin and the urogenital area, simultaneously delivers lactic acid producing bacteria, thereby establishing and maintaining a healthy microbial flora in these areas. The hygiene tissue is impregnated with a composition including a lactic acid producing bacterium / bacteria suspended in a lipid and optionally additional components. Encapsulating the lactic acid producing bacterium in a lipid provides a moisturefree environment enhancing the survival of the bacterium and keeping the bacterium fit for growth after delivery to the skin. By this approach, hygiene tissues, including lactic acid producing bacteria can be stored for long time periods. Also, the hygiene tissue improves the efficiency of transfer of the lactic acid producing bacterium to the skin and urogenital area. In addition, the lipid provides a cleaning function, so that the skin is cleaned simultaneously as the lactic acid bacteria is delivered.